£810 / $1295 / €985
The government drive to support local production and reduce the country's reliance on imports, in addition to global epidemiological and demographic trends, are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities continues to leave the vast majority of the population without medical care. BMI believes this will be rectified through the creation of the National Health Insurance scheme over the next decade, but in the meantime unemployment, lack of education and geographical inaccessibility to healthcare for the wider population will continue to hinder growth in the market.
Headline Expenditure Projections
Pharmaceuticals: ZAR27.19bn (US$3.74bn) in 2011 to ZAR29.61bn (US$3.61bn) in 2012; +8.9% in local currency and -3.5% in US dollar terms.
Healthcare: ZAR261.51bn (US$36.01bn) in 2011 to ZAR285.26bn (US$34.79bn) in 2012; +9.1% in local currency terms and -3.4% in US dollar terms.
Medical devices: ZAR11.43bn (US$1.57bn) in 2011 to ZAR12.19bn (US$1.49bn) in 2012; +6.7% in local currency terms and -5.5% in US dollar terms. Forecast changed due to depreciation of the South African rand.
Risk/Reward Rating: South Africa's composite score is unchanged at 55.5 out of 100, with no shift in position at sixth in the matrix out of 30 markets surveyed in the Middle East and Africa. Despite the country's low risk profile being more favourable than its rewards profile, the country remains one of the most attractive in the MEA region.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.